PMID- 23425609
OWN - NLM
STAT- MEDLINE
DCOM- 20140519
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 15
IP  - 10
DP  - 2013 Oct
TI  - Once weekly exenatide: efficacy, tolerability and place in therapy.
PG  - 871-81
LID - 10.1111/dom.12084 [doi]
AB  - Exenatide once weekly is the first glucose-lowering agent available to patients 
      with type 2 diabetes mellitus (T2DM) which is administered once per week. This 
      long-acting formulation contains the same active ingredient as exenatide twice 
      daily, except that the exenatide is encapsulated in dissolvable microspheres. 
      Following subcutaneous injection, exenatide once weekly microspheres remain in 
      place under the skin and slowly degrade, releasing active exenatide continuously 
      into circulation. In randomized clinical trials, exenatide once weekly was 
      associated with significant glycaemic improvement and moderate weight loss in 
      patients with T2DM when administered as monotherapy or in combination with a 
      variety of oral antidiabetic agents. Exenatide once weekly also lowered blood 
      glucose more effectively than titrated basal insulin in patients on metformin or 
      metformin plus sulphonylurea background therapy. Gastrointestinal side effects 
      (nausea, vomiting and diarrhoea) were the most common tolerability issues 
      associated with exenatide once weekly administration, but they occurred at lower 
      rates than in patients on other glucagon-like peptide receptor agonists (i.e., 
      exenatide twice daily or liraglutide). Issues regarding the place of exenatide 
      once weekly in T2DM pharmacotherapy are discussed.
CI  - (c) 2013 John Wiley & Sons Ltd.
FAU - Wysham, C
AU  - Wysham C
AD  - Department of Medicine, University of Washington School of Medicine, Seattle, WA, 
      USA.
FAU - Grimm, M
AU  - Grimm M
FAU - Chen, S
AU  - Chen S
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130324
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Peptides)
RN  - 0 (Venoms)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9100L32L2N (Metformin)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Blood Glucose/*drug effects/metabolism
MH  - Delayed-Action Preparations/administration & dosage
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Diarrhea/chemically induced
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Exenatide
MH  - Female
MH  - Glycated Hemoglobin/*drug effects/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/pharmacokinetics/pharmacology
MH  - Injections, Subcutaneous
MH  - Male
MH  - Metformin/administration & dosage
MH  - Middle Aged
MH  - Nausea/chemically induced
MH  - Peptides/*administration & dosage/pharmacokinetics/pharmacology
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Venoms/*administration & dosage/pharmacokinetics/pharmacology
MH  - Vomiting/chemically induced
MH  - Weight Loss/*drug effects
OTO - NOTNLM
OT  - GLP-1 analogue
OT  - antidiabetic drug
OT  - incretin therapy
OT  - type 2 diabetes
EDAT- 2013/02/22 06:00
MHDA- 2014/05/20 06:00
CRDT- 2013/02/22 06:00
PHST- 2012/11/02 00:00 [received]
PHST- 2012/11/30 00:00 [revised]
PHST- 2013/02/13 00:00 [accepted]
PHST- 2013/02/22 06:00 [entrez]
PHST- 2013/02/22 06:00 [pubmed]
PHST- 2014/05/20 06:00 [medline]
AID - 10.1111/dom.12084 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2013 Oct;15(10):871-81. doi: 10.1111/dom.12084. Epub 2013 
      Mar 24.